Investigating the Efficacy of Hypomethylating Agents in Treating Acute Myeloid Leukemia

Strategic Insights -

Researchers at the Methodist Hospital Research Institute are conducting a Phase 2 clinical trial to study the efficacy of hypomethylating agents versus standard intensive chemotherapy induction in patients with acute myeloid leukemia (AML). The trial, led by principal investigator Shilpan Shah, MD, aims to enroll 112 adult patients and assess the clinical utility of a novel blood-based epigenetic biomarker, 5-hydroxymethylcytosine (5hmC), in measuring residual disease. The study will compare the efficacy of hypomethylating agent-based therapy versus intensive induction chemotherapy, using the 5hmC biomarker to guide post-induction treatment decisions.

Key Takeaways:

  • The trial is a Phase 2 interventional clinical study to evaluate the efficacy of hypomethylating agents in treating AML.
  • The study will compare the efficacy of hypomethylating agent-based therapy versus intensive induction chemotherapy.
  • The trial will assess the clinical utility of a novel blood-based epigenetic biomarker, 5-hydroxymethylcytosine (5hmC), in measuring residual disease.
  • The study will enroll 112 adult patients and follow them for a defined period to assess primary endpoints such as minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).
  • The trial will collect blood samples at defined intervals to assess MRD status and guide post-induction treatment decisions.
  • The study will be conducted at the Methodist Hospital Research Institute, and the principal investigator is Shilpan Shah, MD.

Statistics:

  • 112 adult patients will be enrolled in the trial.
  • The study will be conducted for an undefined period.
  • The trial will assess the efficacy of hypomethylating agents in treating patients with AML.
  • The primary endpoints of the study include minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).

Sources:

  • ClinicalTrials.gov (Source: https://clinicaltrials.gov/study/NCT07060001)